Skip to main content
Clinical Trials/NCT00772616
NCT00772616
Completed
Phase 4

Influence of Intraoperative Analgesia (Sufentanil Administered According to the Usual Criteria or Remifentanil Administered by a Closed-loop System Using Bispectral Index as the Controller) on the Postoperative Morphine Consumption

Hopital Foch1 site in 1 country60 target enrollmentSeptember 2008

Overview

Phase
Phase 4
Intervention
Remifentanil
Conditions
Anesthesia
Sponsor
Hopital Foch
Enrollment
60
Locations
1
Primary Endpoint
Dose of morphine administered during the postoperative period (patient controlled analgesia)
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Unlike longer acting opiates (sufentanil), remifentanil may provoke postoperative hyperalgesia. We have developed two automated bispectral index - guided drug delivery systems: one for propofol administration, the other for combined propofol and remifentanil administration. Both systems achieve the same objective: similar level of anesthesia indicated by bispectral index levels between 40 to 60. We make the assumption that this method of automated remifentanil administration may avoid postoperative hyperalgesia. Patients scheduled for abdominal surgery will be divided into two groups:

  • in one group, patients will receive automatically delivered propofol and manually delivered sufentanil according to the usual criteria,
  • in the other group, patients will receive propofol and remifentanil both automatically administered.

Assessment of postoperative hyperalgesia will be primarily based on morphine consumption (patient controlled analgesia) and detection of cutaneous hyperalgesia areas.

Registry
clinicaltrials.gov
Start Date
September 2008
End Date
January 2011
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for an abdominal surgery

Exclusion Criteria

  • Age less than 18 years,
  • Pregnant women,
  • Allergy to propofol, sufentanil, remifentanil, morphine, muscle relaxant, or to a component,
  • Hypersensibility to sufentanil, remifentanil or to a derivate of fentanyl,
  • Inflammatory bowel disease,
  • Chronic pain,
  • Patients receiving a psychotropic treatment or a a morphine agonist-antagonist,
  • Alcoholic patients and patients taking opiates,
  • History of neurological disorders or central brain lesion, of severe respiratory insufficiency, of hepatic insufficiency,
  • Emergency surgery

Arms & Interventions

1

Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).

Intervention: Remifentanil

2

Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria

Intervention: Sufentanil

Outcomes

Primary Outcomes

Dose of morphine administered during the postoperative period (patient controlled analgesia)

Time Frame: 48 postoperative hours

Secondary Outcomes

  • postoperative pain scores(48 postoperative hours)
  • postoperative hyperalgesia(up to 5th to 7th postoperative days)
  • nausea vomiting(48 postoperative hours)

Study Sites (1)

Loading locations...

Similar Trials